Defining the Role of the Advanced Practice Provider Within the National Cancer Institute Community Oncology Research Program

Author:

Braun-Inglis Christa M.1ORCID,Dressler Emily V.2ORCID,Myers Jamie S.3ORCID,Benson Al B.4ORCID,Flannery Marie5ORCID,Good Marjorie6ORCID,Denicoff Andrea6,Berenberg Jeffrey L.1ORCID,DeTroye Alisha T.7,O'Brien Bridget8,Kottschade Lisa9ORCID,Omatsu Dee Ann10,Kittel Carol A.2,Nightingale Chandylen L.2ORCID,Foust Melyssa11,Lesser Glenn J.2

Affiliation:

1. University of Hawaii Cancer Center, Honolulu, HI

2. Wake Forest University School of Medicine, Winston-Salem, NC

3. University of Kansas, School of Nursing, Kansas City, KS

4. Northwestern Medicine, Chicago, IL

5. University of Rochester, Rochester, NY

6. NCI, Bethesda, MD

7. Atrium Health Wake Forest Baptist, Winston-Salem, NC

8. Rush University, Chicago, IL

9. Mayo Clinic, Rochester, MN

10. Hawaii Pacific Health, Honolulu, HI

11. Gibbs Cancer Center and Research Institute at Pelham, Greer, SC

Abstract

PURPOSE Oncology advanced practice providers (APPs), including nurse practitioners, clinical nurse specialists, physician assistants, and clinical pharmacists, contribute significantly to quality cancer care. Understanding the research-related roles of APPs in the National Cancer Institute's (NCI) Community Oncology Research Program (NCORP) could lead to enhanced protocol development, trial conduct, and accrual. METHODS The 2022 NCORP Landscape Assessment Survey asked two questions about the utilization and roles of APPs in the NCORP. RESULTS A total of 271 practice groups completed the 2022 survey, with a response rate of 90%. Of the 259 nonpediatric exclusive practice groups analyzed in this study, 92% used APPs for clinical care activities and 73% used APPs for research activities. APPs most often provided clinical care for patients enrolled in trials (97%), followed by assistance with coordination (65%), presenting/explaining clinical trials (59%), screening patients (49%), ordering investigational drugs (37%), and consenting participants (24%). Some groups reported APPs as an enrolling investigator (18%) and/or participating in institutional oversight/selection of trials (15%). Only 5% of NCORP sites reported APPs as a site primary investigator for trials, and very few (3%) reported APPs participating in protocol development. CONCLUSION Practice groups report involving APPs in clinical research within the NCORP network; however, opportunities for growth exists. As team-based care has enhanced clinical practice in oncology, this same approach can be used to enhance successful research. Suggested strategies include supporting APP research-related time, recognition, and education. The findings of this survey and subsequent recommendations may be applied to all adult oncology practices that participate in clinical research.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Oncology (nursing),Health Policy,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3